Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

320
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
320
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

172
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
172
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

256
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
256
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

296
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
296
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

238
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
238
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

256
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
256

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trial.

BMJ open·2026
Same author

Which issues should be addressed in future trials regarding the use of corticosteroids in community acquired pneumonia? A survey of REMAP-CAP investigators.

Intensive care medicine·2026
Same author

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

medRxiv : the preprint server for health sciences·2026
Same author

Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France.

Journal of neuromuscular diseases·2026
Same author

Clinical Criteria for the Definition of Refractory Septic Shock: A Joint Delphi Consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM).

Critical care medicine·2026
Same author

Clinical criteria for the definition of refractory septic shock: a joint Delphi consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM).

Intensive care medicine·2026

Related Experiment Video

Updated: Jul 30, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.8K

Corticosteroids in ARDS.

Emmanuelle Kuperminc1, Nicholas Heming1,2,3, Miguel Carlos1

  • 1Department of Intensive Care, Hôpital Raymond Poincaré, APHP University Versailles Saint Quentin-University Paris Saclay, 92380 Garches, France.

Journal of Clinical Medicine
|May 13, 2023
PubMed
Summary
This summary is machine-generated.

Corticosteroids, potent anti-inflammatory drugs, may help treat acute respiratory distress syndrome (ARDS) due to their effectiveness in sepsis and pneumonia. Further research is needed to optimize their use in ARDS treatment.

Keywords:
acute respiratory distress syndromeglucocorticoidssepsis

More Related Videos

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.5K
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

2.3K

Related Experiment Videos

Last Updated: Jul 30, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.8K
Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.5K
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

2.3K

Area of Science:

  • Critical Care Medicine
  • Pulmonology
  • Pharmacology

Background:

  • Acute respiratory distress syndrome (ARDS) shares inflammatory pathways with sepsis.
  • Corticosteroids are established treatments for septic shock and SARS-CoV-2 related acute respiratory failure.
  • Recent evidence suggests corticosteroids reduce mortality in severe community-acquired pneumonia.

Purpose of the Study:

  • To review the potential role of corticosteroids in treating ARDS.
  • To explore the common pathobiology between ARDS and sepsis.
  • To identify gaps in current research regarding corticosteroid therapy for ARDS.

Main Methods:

  • A narrative review of English language literature published before January 2023.
  • PubMed search using terms: acute respiratory distress syndrome, sepsis, and steroids.
  • Reference list review of selected articles and author expertise.

Main Results:

  • ARDS and sepsis involve excessive inflammation.
  • Corticosteroids are effective anti-inflammatory agents with demonstrated benefits in related conditions.
  • Evidence suggests a potential therapeutic role for corticosteroids in ARDS.

Conclusions:

  • Corticosteroids may offer a treatment option for ARDS.
  • High-quality research is essential to determine optimal corticosteroid timing, dosage, and duration for ARDS.
  • Further investigation is needed to fully elucidate the role of steroids in ARDS management.